CalciMedica

Earlier this week we shared the news that the first patient has been dosed in #KOURAGE, our Phase 2 trial evaluating Auxora for the treatment of severe acute kidney injury with associated acute hypoxemic respiratory failure (AHRF). There are currently no approved therapies for AKI and we look forward to continuing to evaluate Auxora as a potential treatment for this severe and underserved disease. See our press release: https://lnkd.in/e8HzWKjJ

Today we announced that the first patient has been dosed in #KOURAGE, our Phase 2 trial evaluating Auxora for the treatment of severe #acutekidneyinjury with associated acute hypoxemic respiratory failure (AHRF). We expect to share topline data from this trial in 2025. Read the press release: https://lnkd.in/eRmNxsik

We are excited to share that today we announced positive topline data from our Phase 2b CARPO trial of #Auxora in #acutepancreatitis (AP). The trial established a dose response for Auxora across multiple endpoints, identified both the target patient population and the likely drug dose for a pivotal trial, and re-affirmed Auxora’s safety profile and tolerability as seen in prior clinical trials. Read the press release: https://lnkd.in/gAgBCaAW

We recently completed enrollment in our ongoing Phase 2b clinical trial, CARPO, which is evaluating Auxora™ in patients with #acutepancreatitis with accompanying SIRS. For details on the clinical trial, visit https://lnkd.in/eTwrEFCa, or hear some of our study investigators discuss the potential for #Auxora to improve outcomes for patients with AP.

Today we announced that the last patient has been enrolled in our Phase 2b CARPO trial of Auxora™ in #acutepancreatitis (AP). Details here: https://lnkd.in/eqjarCww

Today CalciMedica reported financial results for the year ended December 31, 2023. Read the press release here: https://lnkd.in/eEFNhNSK

Yesteday we presented data from preclinical studies of Auxora in acute kidney injury at the 29th International AKI & CRRT Conference. The data show that Auxora hastens recovery of kidney function and improves survival in a rat model of #AKI. https://lnkd.in/g5h4vxbY

We are very excited announce that the U.S. FDA has accepted our IND application for Auxora for the treatment of acute kidney injury (AKI). We plan to initiate a Phase 2 trial in severe AKI, called KOURAGE, in the first half of 2024. With this study, we aim to address the high unmet need for patients suffering from stage 2 and stage 3 AKI, a serious, acute illness with high mortality rates. Read the press release: https://lnkd.in/e6GnuRV7

CalciMedica will participate in a presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14. Details here: https://lnkd.in/eSz7X4Km

Today CalciMedica announced that we have raised up to approximately $55 million in financing, with participation from new healthcare-dedicated investors, including an affiliate of Deerfield Management, Soleus Capital, Stonepine Capital Management and Aisling Capital, as well as existing investors Sanderling Ventures and Bering Capital. Read more in the press release: https://lnkd.in/ehQHqC_g